1. Home
  2. SYRE vs KOP Comparison

SYRE vs KOP Comparison

Compare SYRE & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYRE
  • KOP
  • Stock Information
  • Founded
  • SYRE 2013
  • KOP 1988
  • Country
  • SYRE United States
  • KOP United States
  • Employees
  • SYRE N/A
  • KOP N/A
  • Industry
  • SYRE Biotechnology: Pharmaceutical Preparations
  • KOP Forest Products
  • Sector
  • SYRE Health Care
  • KOP Basic Materials
  • Exchange
  • SYRE Nasdaq
  • KOP Nasdaq
  • Market Cap
  • SYRE 841.4M
  • KOP 674.1M
  • IPO Year
  • SYRE 2016
  • KOP 2006
  • Fundamental
  • Price
  • SYRE $15.72
  • KOP $34.18
  • Analyst Decision
  • SYRE Buy
  • KOP Buy
  • Analyst Count
  • SYRE 6
  • KOP 1
  • Target Price
  • SYRE $55.00
  • KOP $64.00
  • AVG Volume (30 Days)
  • SYRE 673.0K
  • KOP 127.1K
  • Earning Date
  • SYRE 08-06-2025
  • KOP 08-07-2025
  • Dividend Yield
  • SYRE N/A
  • KOP 0.94%
  • EPS Growth
  • SYRE N/A
  • KOP N/A
  • EPS
  • SYRE N/A
  • KOP 1.22
  • Revenue
  • SYRE N/A
  • KOP $2,051,000,000.00
  • Revenue This Year
  • SYRE N/A
  • KOP N/A
  • Revenue Next Year
  • SYRE N/A
  • KOP $2.61
  • P/E Ratio
  • SYRE N/A
  • KOP $27.79
  • Revenue Growth
  • SYRE N/A
  • KOP N/A
  • 52 Week Low
  • SYRE $10.91
  • KOP $22.99
  • 52 Week High
  • SYRE $40.26
  • KOP $41.64
  • Technical
  • Relative Strength Index (RSI)
  • SYRE 51.34
  • KOP 59.98
  • Support Level
  • SYRE $14.97
  • KOP $32.92
  • Resistance Level
  • SYRE $16.92
  • KOP $35.61
  • Average True Range (ATR)
  • SYRE 1.12
  • KOP 1.05
  • MACD
  • SYRE 0.02
  • KOP 0.09
  • Stochastic Oscillator
  • SYRE 58.05
  • KOP 65.50

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

Share on Social Networks: